What are the contraindications for Tamiflu (oseltamivir) in patients with a history of kidney disease, seizures, or psychiatric disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Contraindications for Tamiflu (Oseltamivir)

The only absolute contraindication to oseltamivir is known serious hypersensitivity to oseltamivir or any component of the formulation. 1

Absolute Contraindication

  • Serious hypersensitivity reactions (including anaphylaxis, severe rash, or angioedema) to oseltamivir or any ingredient in the formulation represent the sole FDA-labeled contraindication. 1

Critical Dosing Adjustments (Not Contraindications, But Required Modifications)

Renal Impairment

  • Creatinine clearance 30-60 mL/min: Reduce dose to 30 mg twice daily for treatment. 2
  • Creatinine clearance 10-30 mL/min: Reduce dose to 75 mg once daily for treatment and 75 mg every other day for prophylaxis. 3, 2
  • Routine dialysis patients: No established dosing recommendations exist; use with extreme caution. 3
  • The active metabolite (oseltamivir carboxylate) accumulates significantly in renal impairment, increasing adverse reaction risk. 3, 2

Hepatic Dysfunction

  • No dose adjustment or contraindication exists for liver disease, as oseltamivir has not been formally studied in hepatic dysfunction. 3, 4
  • The CDC and ACIP explicitly state no specific warnings or contraindications for hepatic impairment. 4
  • Metabolism occurs via hepatic esterases, but elimination is predominantly renal (80%), making hepatotoxicity unlikely at therapeutic doses. 4

Special Populations Requiring Heightened Monitoring (Not Contraindications)

Seizure Disorders

  • Seizure events have been reported during postmarketing surveillance with oseltamivir, but no epidemiologic studies demonstrate increased seizure risk. 3
  • Unlike amantadine (which shows clear increased seizure incidence), oseltamivir lacks definitive causality data. 3
  • Proceed with oseltamivir in seizure patients when influenza treatment is indicated, as the mortality benefit outweighs theoretical seizure concerns. 3

Psychiatric Disorders

  • Neuropsychiatric events (delirium, hallucinations, suicidal behavior, agitation) have been reported, particularly in children and adolescents. 5, 6
  • These events occurred primarily in Japanese populations and may be confounded by influenza-associated encephalopathy itself. 5
  • A 74-year-old with mild neurocognitive disorder developed new psychiatric symptoms on oseltamivir prophylaxis that resolved completely upon discontinuation. 6
  • Psychiatric history is not a contraindication, but close monitoring is essential, especially in patients with pre-existing neurocognitive disorders. 6

Clinical Pitfalls to Avoid

  • Do not withhold oseltamivir in high-risk patients (immunocompromised, chronic cardiac/respiratory disease, age >65, pregnancy, hospitalized) based on theoretical concerns about seizures or psychiatric effects—influenza mortality risk exceeds medication risk. 4
  • Always calculate creatinine clearance rather than relying on serum creatinine alone, especially in elderly patients where renal function declines with age despite normal creatinine. 2
  • Administer with food to reduce nausea and vomiting (occurs in 10-14% of patients) without affecting absorption. 2, 7, 8
  • Initiate within 48 hours of symptom onset for maximum therapeutic benefit. 2

References

Guideline

Oseltamivir Dosing in Patients with Influenza and Underlying Kidney and Heart Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Oseltamivir Use in Patients with Elevated Liver Function Tests

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Oseltamivir: neuropsychiatric disorders.

Prescrire international, 2007

Guideline

Tamiflu and Eliquis Interaction Assessment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.